Pharming Group NV (PHAR): Price and Financial Metrics


Pharming Group NV (PHAR): $13.25

0.19 (+1.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHAR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHAR Stock Summary

  • PHAR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.53 -- higher than only 4.94% of US-listed equities with positive expected earnings growth.
  • PHAR's went public 1.94 years ago, making it older than merely 8.99% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of -90.08%, PHARMING GROUP NV's debt growth rate surpasses just 1.46% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to PHARMING GROUP NV, a group of peers worth examining would be SPNS, THRM, DNAY, BJDX, and HOLI.
  • To check out PHARMING GROUP NV's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001828316.

PHAR Stock Price Chart Interactive Chart >

Price chart for PHAR

PHAR Price/Volume Stats

Current price $13.25 52-week high $13.25
Prev. close $13.06 52-week low $6.10
Day low $12.28 Volume 8,400
Day high $13.25 Avg. volume 5,149
50-day MA $10.76 Dividend yield N/A
200-day MA $9.44 Market Cap 864.96M

Pharming Group NV (PHAR) Company Bio


Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.


PHAR Latest News Stream


Event/Time News Detail
Loading, please wait...

PHAR Latest Social Stream


Loading social stream, please wait...

View Full PHAR Social Stream

Latest PHAR News From Around the Web

Below are the latest news stories about PHARMING GROUP NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.

Investing in Pharming Group (AMS:PHARM) a year ago would have delivered you a 59% gain

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Yahoo | November 28, 2022

Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Yahoo | November 23, 2022

Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting

Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that new clinical data for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, an investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be presented by V. Koneti Rao, MD, FRCPA, staff physician in the Primary Immune Deficiency Clinic at the National Institute of Health in Bethesda, Maryl

Yahoo | November 23, 2022

Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?

Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Yahoo | November 8, 2022

Pharming to present at Jefferies Healthcare Conference

Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference in London, November 15-17, 2022.

Yahoo | November 3, 2022

Read More 'PHAR' Stories Here

PHAR Price Returns

1-mo 21.90%
3-mo N/A
6-mo 55.88%
1-year 74.80%
3-year N/A
5-year N/A
YTD 48.21%
2021 -41.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5733 seconds.